everyone. Tiffany. Thanks, morning, Good
African shareholders, on of sustainable and the to as the the up, swine results, our They the fever X stand last integration separation Health customers, focused and moving the systems have to difficult overcome the and Animal for other. for long-term remains team want accelerating pandemics, and environment. in independent challenges Bayer of have each stayed value acknowledge yourselves Before QX I what a and in they both our that years COVID completion through
to hard we years out over all you made of Four decisions these several decisions. the know, As stand in strategic me. X Elanco, past have
a from the strategy Today, well Animal and are that Bayer execution seeing our sets not transforming of global profits truly believe strong the August from be started Elanco changing restructuring. leader. accelerating closed and acquisition choices to in with since momentum also we sales, as on our and commercial shown those health XXXX animal as the disciplined acquisition Bayer building XXXX. the our the IPO, EBITDA, payoff after path I Health Elanco on business long has the distributor leadership we First, a better-than-expected
results billion across Turning of outperformance surpassed $X.XXX X, our $XX to quarter range over of QX geographies. and by on first the categories revenue midpoint Slide with guidance million, our broad-based many
and flow-through $X.XX $XXX above midpoint Our leverage to landed execution driving adjusted expense adjusted EPS $X.XX strong EBITDA bring the of synergy guidance, to with of million.
Our X to the reflected expectation XXXX, momentum adjusted increased operational adjusted our remain innovation on track is EPS. $XXX million contribute $XX in million launches This and to for for full this revenue sales year continued in revenue, guidance which execution EBITDA and year. in includes
a and filing more also Our in separate a event and and in adverse regulators data, on to to IPP in expanded raised provided X-K of I be through comprehensive regarding in would our directly reports spread of algorithm. detailed to review moment demonstrates Today, we we outlook execution released quarter. X to line Slides collar. strategy legislators. an before address progressing the Seresto correct first our additional misinformation and scientific continues tick against growth data media The which a conclusions have filing, flea with from includes our to a X Seresto performance like long-term take strength the our review to
who what companionship at do is me core we well-being let First and people and the we their and pets health and the of lives of foremost, emphasize ability Elanco. enrich to are the to through
and pet’s our brand. risk protect this tirelessly quality their That’s ticks has stories to a using and which pets impact safe to danger harmful One worked their transmit non-use why owners. fleas life. disease around of proven can and team these trusted safety owners The pet from that of around clarify presents from potential the science to is dangerous our greatest products stop potentially and concerns pets
Seresto. So, summarize be me let and clear on
First, the more pharmacovigilance to registrations and around active no in ingredients studies profile deaths. bodies is Also, robust the XX than pet product’s regulatory safety by scientific world evidence Seresto’s cause strong that substantiate clinical supported reporting process. is our pharmacovigilance from or there
we the Seresto on to record We subcommittee shared are of additional policy product the to and surveillance providing set straight. and with information have the on Representatives information EPA economic House consumer
for with both actively to request We on supplemental any cooperate facts. continue
levels research owners, Our pet the retailers and proactive high clinics. and efforts our by bolstered proprietary veterinarians, share market facts veterinary with consumers indicates of among confidence to
possibly Coating. and year of of full system the U.S. is ahead we Since U.S. more the trends. think deviation robust the from pharmacovigilance Seresto collar been to of track by our expectations on quarter, in no have first details I global across XX brand. the revenue, particularly recognized Through XXXX classified the few are the terms than historical original in an Seresto we Importantly, expectations growth been XX.X Seresto pet [indiscernible] known in the XXXX, for the I to deaths distributed classification Seresto million a X-year in using towards would in start are as April saw internationally probably compared for launch like our caused revenue noteworthy. collars highlight of as investigation have or process,
highly to none XX this third-party As rate sold, an but as collar getting of either in deemed a an results Seresto. Seresto recently very the since reflect incident collars ingredients the linked object caught X.XXXXXX% were unfortunate percentage active unlikely, in an in of and cases resulting of cases independent as on such importantly, harm. situations The causally those by total and review, XXXX reinforced
any disappointed associated occurs reaction are a or adverse deeply We event with when product.
we In taken the of steps proactive of light misinformation last over consumer ensure safety the products. to dedicated team strong product’s around Elanco our understanding X quality, is and the entire profile. safety Seresto Our to ensuring the of have months, efficacy the
online We consumer veterinary across advertising materials in-store directly have at enhanced retailer and and multi-year through trends. offered to educational XX,XXX clinics
X-year Looking growth, January. was U.S. growth to XXXXdata from The versus Seresto February a and and our in above XXXX. up and view first of trends dispensing XX% Kynetec, revenue retail of Nielsen closest quarter Global owner March X-year represents data first XXXX veterinary quarter weather impacted well at were purchasing. closer pet the
While it a we context not case. in basis, intend we believe report on provides dispensing do data regular important this to
returns. increases Additionally, share me have Seresto let in not seen any material that we
To omni-channel efforts and we the long are second engagement we in in and fuel with Looking a for to additional to pet runway in U.S. customers investing growth, quarter. see new trusted forward, owners, that investments our digital reach including the relationship continue deepen this brand. current
over market initiatives Continued and and opportunity creates plan ample emerging unique connected trusted management for in expansion platform markets, key including building lifecycle and brand. care as this a China as time well
reflected price posting the is increase backdrop. leadership strong In Moving in driver growth. global saw our distribution The also now in fourth a to XX%. X, million the was accelerated international with drove the and including were in overall industry quarter, revenue a Pet creating strong robust of quarter And prior of competitive, pet beneficial operational at family real double-digit up Elanco. new China. markets, a midpoint reinforces revenue upside U.S. performed remain aggregate quarter, $XXX business, clinic X% key the favorable quarter, global August. and retail. EDI Advantage in half reflecting particular from under U.S. U.S. with but working for in well the In the Slide in the Health, of parasiticides, the the quarters. remained Growth at the health efforts vet and of strategy good targeted versus strength discipline on demand. in health It that total the approximately achieved and guidance, global our channel the consumer levels backdrop. execution channel Pet for last across quarter business installed retention inventory including trends million, reaching Credelio our vaccines vaccines, for $XXX especially consistent
in pet the owners, the and beginning with our difficult first quarter Trifexis, leadership in comprehensive Interceptor and for offering is continues expectations omni-channel erosion key to were continues line as tick growth worm veterinarians well with of cycle one consumer-driven resonate revenue the industry coverage. five share comparisons to and channel by from Credelio the pairing despite this the Plus enablers, as retail us defend flea, demand. Our opportunity brand, quarter industry to positions our innovation. see our outgrew Meanwhile,
Galliprant the and in the to as declines ahead this first the share managing profitability omni-channel market, at clinic. a retail in the optimizing targeted a is with growth also offset are growth through efforts, older Galliprant bit in brand decreases running for in therapeutics, Europe. once In again to had acting Trifexis robust partial data. NSAID expectations according our double-digit with gains quarter U.S. Kynetec of We
Overall, in brand commercial dosing working its at-home are in pet head remainder health health in view optimistic, the but into expectations February. and with global grow through first-line positioning from We of our pet encouraged be to year exceeding business. the last earnings am to through the our balanced We treatment easy our tenth blockbuster an our by I for the with strategy as continued execution the our expansion. call first quarter,
digital from competitive upcoming ecosystem, innovation, growing the omni-channel our and market, the selected and year in recognizing channel while leveraging full growth Our Chinese expanding optimizing including health nature increased of new pet leadership, our industry. guidance partners recent the fast geographies, incorporates highly
saw to saw the normalized economics. the COVID businesses to pressure continue Farm Turning the U.S. XXXX. pressure fee stabilization Elevated in backdrop Cattle now business, our in Swine we we first producer the costs from in quarter, Animal & has as
generic our However, and outperformed they Rumensin, assumptions we continue quarter. and like which products Optaflexx forecast expectations. value for With proposition line to the in the with competition in our our navigate our enhance remain Rumensin, share efficiency
a from consumption. aqua poultry by to benefited we into impacted tailwind U.S. in the implants, U.S., not competitor the Outside and and cattle be quarter. extending do anticipate we conditions macroeconomic stock-outs negatively and second continue unfavorable Finally, vaccines reduced
international shared in have markets. challenges we are emerging previously, midsized concentrated As poultry
While is encouraged and were very significant aqua, to for differences quarter. In the improving, remain we global see the between poultry prices countries poultry outlook industry positive competitive. first inflect global end salmon is to trade gradually year-over-year still the
costs our for in businesses trends then We for headwinds, And midyear China around Elanco herd poultry driven by again remain and continue quarter quarter. more spikes strong of the is fever while The the reduction course pandemic related as to improve under swine, recovery producers third important growth quarter international over reduction outbreaks. new headwinds. and as African potential another of are economic-related prices Both look likely second the and impact fee. species and reduced finally, sow swine pressure to new down herd ASF vigilant expensive saw from in with with remaining Chinese higher over to time. herd of impact sow the well XX% we ASF aqua from quarter drivers
percentage across revenue Elanco We total to China continue and to in XXXX. to swine, pet point expect of growth health contributing poultry X
bringing is of XXXX. part that international, finally, Health, Our split. The our commercial changing including first generating demand several strategy distribution pace health are and mix, Europe XX% quarter results changing reflect our progress to synergy acquisition and the our execution U.S. Farm Pet U.S. Bayer XX% as and our that in the across pet leadership teams our areas, XX:XX farm revenue accelerated of animal underlying new in Animal, from key a capture,
you As or strengthened comes execute and see in against on and innovation expanded as our our portfolio quarter the Slide continue strategy, will we IPP. to X, outperformance productivity first
this the provide launch of Slide planned excellence. with and to Turning like received to status launches focus would XX XX a year, and turning towards the the I for geographic X, now approvals execution X
today. reduce to well Farm customers and and shipped the its Increxxa fed in tranche competitive first in indicated of being our lock to Animal first gas the Experior, first a quarter emissions the of meeting and weight the market product the performing to expectations kind ammonia feed carcass as is part cattle, first its EU cattle per pound side, U.S. in of of launches On is is
which introducing We has products now portfolio are ZoaShield, necessary to heat without formulation. Cosabody and raised and the sourced which build space. supplement, support in to a RWA we first These market, externally this Clinicox, which two stable key achieved our nutritional antibiotics, join in products two the launched or the quarter
Credelio February, of pet the health, Japan shared to in the Moving as in year. at we Plus launched beginning
parasiticide quarter way the feline our have have the the received Cat season. third as the made marketing our Australia will in We more integration And With the in and that, a quarter clearing for track in Health second launch, to now the Bayer authorization I remains rapid finally, on independent on U.S., EU, to turn portfolio. on outlook. Elura for and for the local time while color launched a as growing provide being Todd call adding Animal our our to progress standup well Credelio results,
